<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Ischemic brain injury resulting from <z:hpo ids='HP_0001297'>stroke</z:hpo> arises from primary neuronal losses and by <z:mp ids='MP_0001845'>inflammatory responses</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous studies suggest that erythropoietin (EPO) attenuates both processes </plain></SENT>
<SENT sid="2" pm="."><plain>Although EPO is clearly antiapoptotic for neurons after experimental <z:hpo ids='HP_0001297'>stroke</z:hpo>, it is unknown whether EPO also directly modulates EPO receptor (EPO-R)-expressing glia, microglia, and other inflammatory cells </plain></SENT>
<SENT sid="3" pm="."><plain>In these experiments, we show that recombinant human EPO (rhEPO; 5,000 U/kg body weight, i.p.) markedly reduces astrocyte activation and the recruitment of leukocytes and microglia into an infarction produced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in rats </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced production of the proinflammatory cytokines <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor, interleukin 6, and monocyte chemoattractant protein 1 concentration is reduced by &gt;50% after rhEPO administration </plain></SENT>
<SENT sid="5" pm="."><plain>Similar results were also observed in mixed neuronal-glial cocultures exposed to the neuronal-selective toxin trimethyl tin </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, rhEPO did not inhibit cytokine production by astrocyte cultures exposed to neuronal homogenates or modulate the response of human peripheral blood mononuclear cells, rat glial cells, or the brain to <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that rhEPO attenuates <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:mp ids='MP_0001845'>inflammation</z:mp> by reducing neuronal <z:hpo ids='HP_0011420'>death</z:hpo> rather than by direct effects upon EPO-R-expressing inflammatory cells </plain></SENT>
</text></document>